Erratum: Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial (The Lancet (2017) 389(10064) (56–66)(S0140673616324539)(10.1016/S0140-6736(16)32453-9));Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial

The Lancet

Volumn 389, Issue 10064, 2017, Pages 56-66

  Bruix, Jordi ^a   Qin, Shukui ^b   Merle, Philippe ^c   Granito, Alessandro ^d   Huang, Yi Hsiang ^e   Bodoky, György ^f   Pracht, Marc ^g   Yokosuka, Osamu ^h   Rosmorduc, Olivier ⁱ   Breder, Valeriy ^j   Gerolami, René ^k   Masi, Gianluca ^l   Ross, Paul J ^m   Song, Tianqiang ⁿ   Bronowicki, Jean Pierre ^o   Ollivier Hourmand, Isabelle ^p   Kudo, Masatoshi ^q   Cheng, Ann Lii ^r   Llovet, Josep M ^a,s,t   Finn, Richard S ^u   LeBerre, Marie Aude ^v   Baumhauer, Annette ^w   Meinhardt, Gerold ^x   Han, Guohong ^y   more..

^a UNIVERSITY OF BARCELONA   (Spain)

^b People's Liberation Army Cancer Center of Nanjing Bayi Hospital   (China)

^c Department of Orthopaedic Surgery   (France)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e NATIONAL YANG MING UNIVERSITY   (Taiwan)

^f St László Teaching Hospital   (Hungary)

^g CENTRE EUGÈNE MARQUIS   (France)

^h CHIBA UNIVERSITY   (Japan)

ⁱ PITIÉ SALPÊTRIÈRE HOSPITAL   (France)

^j N N BLOKHIN RUSSIAN CANCER RESEARCH CENTER   (Russian Federation)

^k TIMONE HOSPITAL   (France)

^l UNIVERSITY HOSPITAL OF PISA   (Italy)

^m KING'S COLLEGE HOSPITAL NHS FOUNDATION TRUST   (United Kingdom)

ⁿ TIANJIN MEDICAL UNIVERSITY   (China)

^o UNIVERSITÉ DE LORRAINE   (France)

^p CAEN UNIVERSITY HOSPITAL   (France)

^q KINKI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r NATIONAL TAIWAN UNIVERSITY HOSPITAL   (Taiwan)

^s MOUNT SINAI SCHOOL OF MEDICINE   (United States)

^t INSTITUCIÓ CATALANA DE RECERCA I ESTUDIS AVANÇATS ICREA   (Spain)

^u UNIVERSITY OF CALIFORNIA   (United States)

^v Bayer Healthcare SAS   (France)

^w BAYER PHARMA AG   (Germany)

^x BAYER CORPORATION   (United States)

^y FOURTH MILITARY MEDICAL UNIVERSITY   (China)

more..

Author keywords

[No Author keywords available]

Indexed keywords

ALANINE AMINOTRANSFERASE; ALPHA FETOPROTEIN; ASPARTATE AMINOTRANSFERASE; PLACEBO; REGORAFENIB; SORAFENIB; ANTINEOPLASTIC AGENT; CARBANILAMIDE DERIVATIVE; NICOTINAMIDE; PYRIDINE DERIVATIVE;

ADULT; AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ALPHA FETOPROTEIN BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BLEEDING; CANCER CHEMOTHERAPY; CANCER CONTROL; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER SURVIVAL; CHILD PUGH SCORE; CONTROLLED STUDY; DIARRHEA; DOUBLE BLIND PROCEDURE; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FEMALE; FOLLOW UP; HAND FOOT SYNDROME; HUMAN; HYPERTENSION; INTENTION TO TREAT ANALYSIS; INTERACTIVE VOICE RESPONSE SYSTEM; LIVER CELL CARCINOMA; LIVER FAILURE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; MULTIPLE CYCLE TREATMENT; OVERALL SURVIVAL; PARALLEL DESIGN; PHASE 3 CLINICAL TRIAL; PRIORITY JOURNAL; PROGRESSION FREE SURVIVAL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TREATMENT DURATION; TUMOR VOLUME; ANALOGS AND DERIVATIVES; CARCINOMA, HEPATOCELLULAR; CLINICAL TRIAL; KAPLAN MEIER METHOD; LIVER NEOPLASMS; MIDDLE AGED; TREATMENT OUTCOME;

AGED; ANTINEOPLASTIC AGENTS; CARCINOMA, HEPATOCELLULAR; DOUBLE-BLIND METHOD; FEMALE; HUMANS; KAPLAN-MEIER ESTIMATE; LIVER NEOPLASMS; MALE; MIDDLE AGED; NIACINAMIDE; PHENYLUREA COMPOUNDS; PYRIDINES; TREATMENT OUTCOME;

EID: 85007560261     PISSN: 01406736     EISSN: 1474547X     Source Type: Journal    
DOI: 10.1016/S0140-6736(16)32615-0     Document Type: Erratum

References (31)

1. 1 Bruix, J, Sherman, M, Management of hepatocellular carcinoma: an update. Hepatology 53 (2011), 1020–1022.
2. 2 Llovet, JM, Ducreux, M, Lencioni, R, et al. EASL-EORTC clinical practice guidelines: management of hepatocellular carcinoma. J Hepatol 56 (2012), 908–943.
3. 3 Kudo, M, Matsui, O, Izumi, N, et al. JSH Consensus-based clinical practice guidelines for the management of hepatocellular carcinoma: 2014 update by the Liver Cancer Study Group of Japan. Liver Cancer 3 (2014), 458–468.
4. 4 Llovet, JM, Ricci, S, Mazzaferro, V, et al. Sorafenib in advanced hepatocellular carcinoma. N Engl J Med 359 (2008), 378–390.
5. 5 Cheng, AL, Kang, YK, Chen, Z, et al. Efficacy and safety of sorafenib in patients in the Asia-Pacific region with advanced hepatocellular carcinoma: a phase III randomised, double-blind, placebo-controlled trial. Lancet Oncol 10 (2009), 25–34.
6. 6 Cheng, AL, Kang, YK, Lin, DY, et al. Sunitinib versus sorafenib in advanced hepatocellular cancer: results of a randomized phase III trial. J Clin Oncol 31 (2013), 4067–4075.
7. 7 Johnson, PJ, Qin, S, Park, JW, et al. Brivanib versus sorafenib as first-line therapy in patients with unresectable, advanced hepatocellular carcinoma: results from the randomized phase III BRISK-FL study. J Clin Oncol 31 (2013), 3517–3524.
8. 8 Cainap, C, Qin, S, Huang, WT, et al. Linifanib versus sorafenib in patients with advanced hepatocellular carcinoma: results of a randomized phase III trial. J Clin Oncol 33 (2015), 172–179.
9. 9 Zhu, AX, Rosmorduc, O, Evans, TR, et al. SEARCH: a phase III, randomized, double-blind, placebo-controlled trial of sorafenib plus erlotinib in patients with advanced hepatocellular carcinoma. J Clin Oncol 33 (2015), 559–566.
10. 10 Abou-Alfa, GK, Niedzwieski, D, Knox, JJ, et al. Phase III randomized study of sorafenib plus doxorubicin versus sorafenib in patients with advanced hepatocellular carcinoma (HCC): CALGB 80802 (Alliance). Proc Am Soc Clin Oncol, 34, 2016 abstr 4003.
11. 11 Llovet, JM, Decaens, T, Raoul, JL, et al. Brivanib in patients with advanced hepatocellular carcinoma who were intolerant to sorafenib or for whom sorafenib failed: results from the randomized phase III BRISK-PS study. J Clin Oncol 31 (2013), 3509–3516.
12. 12 Zhu, AX, Kudo, M, Assenat, E, et al. Effect of everolimus on survival in advanced hepatocellular carcinoma after failure of sorafenib: the EVOLVE-1 randomized clinical trial. JAMA 312 (2014), 57–67.
13. 13 Zhu, AX, Park, JO, Ryoo, BY, et al. Ramucirumab versus placebo as second-line treatment in patients with advanced hepatocellular carcinoma following first-line therapy with sorafenib (REACH): a randomised, double-blind, multicentre, phase 3 trial. Lancet Oncol 16 (2015), 859–870.
14. 14 Abou-Alfa, GK, Qin, S, Ryoo, BY, et al. Phase III randomized study of second-line ADI-peg 20 (A) plus best supportive care versus placebo (P) plus best supportive care in patients (pts) with advanced hepatocellular carcinoma (HCC). Proc Am Soc Clin Oncol, 34, 2016 abstr 4017.
15. 15 Wilhelm, SM, Dumas, J, Adnane, L, et al. Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity. Int J Cancer 129 (2011), 245–255.
16. 16 Abou-Elkacem, L, Arns, S, Brix, G, et al. Regorafenib inhibits growth, angiogenesis, and metastasis in a highly aggressive, orthotopic colon cancer model. Mol Cancer Ther 12 (2013), 1322–1331.
17. 17 Wilhelm, SM, Carter, C, Tang, L, et al. BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res 64 (2004), 7099–7109.
18. 18 Grothey, A, Van Cutsem, E, Sobrero, A, et al. Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 303–312.
19. 19 Demetri, GD, Reichardt, P, Kang, YK, et al. Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial. Lancet 381 (2013), 295–302.
20. 20 Stivarga Prescribing Information, 2016, Bayer HealthCare Pharmaceuticals, Whippany, NJ.
21. 21 Bruix, J, Tak, WY, Gasbarrini, A, et al. Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study. Eur J Cancer 49 (2013), 3412–3419.
22. 22 Lencioni, R, Llovet, JM, Modified RECIST (mRECIST) assessment for hepatocellular carcinoma. Semin Liver Dis 30 (2010), 52–60.
23. 23 Bruix, J, Reig, M, Sherman, M, Evidence-based diagnosis, staging, and treatment of patients with hepatocellular carcinoma. Gastroenterology 150 (2016), 835–853.
24. 24 Steel, JL, Eton, DT, Cella, D, Olek, MC, Carr, BI, Clinically meaningful changes in health-related quality of life in patients diagnosed with hepatobiliary carcinoma. Ann Oncol 17 (2006), 304–312.
25. 25 Pickard, AS, Neary, MP, Cella, D, Estimation of minimally important differences in EQ-5D utility and VAS scores in cancer. Health Qual Life Outcomes, 5, 2007, 70.
26. 26 Reig, M, Rimola, J, Torres, F, et al. Postprogression survival of patients with advanced hepatocellular carcinoma: rationale for second-line trial design. Hepatology 58 (2013), 2023–2031.
27. 27 Bruix, J, Sherman, M, Llovet, JM, et al. Clinical management of hepatocellular carcinoma. Conclusions of the Barcelona-2000 EASL conference. European Association for the Study of the Liver. J Hepatol 35 (2001), 421–430.
28. 28 Mazzoccoli, G, Miele, L, Oben, J, Grieco, A, Vinciguerra, M, Biology, epidemiology, clinical aspects of hepatocellular carcinoma and the role of sorafenib. Curr Drug Targets 17 (2016), 783–799.
29. 29 Llovet, JM, Peña, CE, Lathia, CD, et al. Plasma biomarkers as predictors of outcome in patients with advanced hepatocellular carcinoma. Clin Cancer Res 8 (2012), 2290–2300.
30. 30 Zhu, AX, Kang, YK, Rosmorduc, O, et al. Biomarker analyses of clinical outcomes in patients with advanced hepatocellular carcinoma treated with sorafenib with or without erlotinib in the SEARCH trial. Clin Cancer Res 22 (2016), 4870–4879.
31. 31 Reig, M, Torres, F, Rodriguez-Lope, C, et al. Early dermatologic adverse events predict better outcome in HCC patients treated with sorafenib. J Hepatol 61 (2014), 318–324.